SNY vs ABT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SNY · Sanofi$47.04 ▲ 0.28%
ABT · Abbott Laboratories$109.93 ▼ 3.23%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SNY -2.0%
- ABT -11.1%
Head to head
| Metric | SNY | ABT |
|---|---|---|
| Price | $47.04 | $109.93 |
| Change today | ▲ 0.28% | ▼ 3.23% |
| Market cap | $112.71B | $190.39B |
| Return, 3 months | +8.2% | +1.2% |
| Return, year to date | +2.4% | -10.6% |
| Return, 1 year | 0.0% | -11.4% |
| P/E (TTM) | 24.1 | 40.9 |
| P/B | 1.4 | 3.7 |
| P/E percentile vs own 5y | 84th | 100th |
| Dividend yield | 4.99% | 2.26% |
| Revenue growth (YoY, latest qtr) | +15.7% | +14.5% |
| Net profit growth (YoY) | +7.9% | -44.0% |
| Gross margin | 73.4% | 56.9% |
| Operating margin | 21.6% | 13.8% |
| Net margin | 8.2% | 9.7% |
| Return on equity | 5.7% | – |
| Analyst target vs. price | +21.2% | +11.3% |
| Analyst buy share | 0% | 94% |
| RSI (14) | 73 | 59 |
| 30-day volatility | 28.2% | 30.9% |
| Max drawdown, 1 year | -21.1% | -36.1% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ABT is the largest of the group by market value.
- SNY has returned the most over the past year.
- SNY carries the lowest trailing P/E.
- SNY pays the highest dividend yield.
- SNY is growing revenue fastest.
- ABT keeps the most profit per dollar of sales.
- SNY has been the calmest stock over the last 30 days.